FLUKIVER BOVIS 50 MG/ML SOLUTION FOR INJECTION FOR CATTLE
Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
Tabia za bidhaa
(SPC)
15-08-2015
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
CLOSANTEL SODIUM DIHYDRATE
Inapatikana kutoka:
Elanco Animal Health, Eli Lilly and Company Limited
ATC kanuni:
QP52AG09
INN (Jina la Kimataifa):
CLOSANTEL SODIUM DIHYDRATE
Kipimo:
50 Mg/Ml
Dawa fomu:
Solution for Injection
Dawa ya aina:
LM-Licensed Merchant
Kundi la matibabu:
Bovine
Eneo la matibabu:
Closantel
Matibabu dalili:
Endoparasiticide
Idhini hali ya:
Authorised
Idhini ya tarehe:
2012-10-12
Tabia za bidhaa
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
FLUKIVER BOVIS 50 mg/ml Solution for Injection for cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for injection.
Clear yellow to amber solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment and control of liver fluke, gastro-intestinal nematodes and arthropods.
TREMATODES
_Fasciola hepatica_
_Fasciola gigantica_
NEMATODES
_Haemonchus placei_
_Bunostomum phlebotomum_
_Oesophagostomum radiatum_
ARTHROPODS
_Hypoderma bovis_
_Hypoderma lineatum_
Each ml contains:
ACTIVE SUBSTANCE:
Closantel
50
mg
(equivalent to closantel sodium dihydrate
54.375 mg)
EXCIPIENTS:
Propylene glycol
414.4 mg
For the full list of excipients, see section 6.1.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 31/07/2015_
_CRN 7020124_
_page number: 1_
4.3 CONTRAINDICATIONS
See section 4.11.
Do not administer to animals with known hypersensitivity to the active ingredient.
Not for i.v. or i.m. use.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they increase the risk of development of resistance and
could ultimately result in ineffective therapy:
•
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
•
Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of
calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal
Egg Count Reduction Test). Where the results of the test(s) strongly su
Soma hati kamili
